General Discussion

They may have specific limited patents beyond that, but as a veteran of the industry I'd expect generics in 2024.

The FDA lists the "last patent" as 2039, but that does not prevent sale of the drug applicable under other patents which may have expired including composition of matter.

The patent is held by the Korean company SK pharma.

The FDA has had 2 ANDAs submitted already. However, the best information I gather indicates a generic will be available in 2033.

Cenobamate is synthetically simple, with a single chiral center, but that is only part of the story. Formulation and pharmacokinetics may represent be a different problem entirely.

It costs a lot to develop a drug, even a simple drug, and I understand a profit motive, but on the other hand, we need to balance wealth with humanity. I have no simple formula to address this conundrum but certainly I wish you well and I hope you will gather as much assistance as possible in these terrible times and hope for better times for you and all others in need of Healthcare.

For the record, my son was born with a birth defect that often causes severe epilepsy, which happily he did not develop. I therefore appreciate the urgency of your care. Unfortunately we now have a government which appreciates nothing other than cruel greed.